Dr Lisa M. Nijm

Loteprednol etabonate suspension 0.25% demonstrates anti-inflammatory action and produces significant improvement in conjunctival hyperaemia and ocular discomfort.

Patients can benefit from short-term, on-label treatment with a novel loteprednol formulation.

Cyclosporine for dry eye disease appears to be efficacious at all levels and the choice of which formulation to use usually depends on tolerability and affordability. Tolerability hinges primarily on the vehicle, which varies among different products.